Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject at least 18 years of age.~* Subject is a candidate for ventilation imaging.~* Subject must be willing and able to provide informed consent.~* Subject must be stable and able to undergo Xe-133 planar imaging and Technegas planar imaging.~* Subject must be willing and agree to complete study procedures.~* Subject is using adequate birth control, if female and fertile. Adequate birth control is defined as surgical sterilization, hormone contraceptive use or intrauterine device (IUD).~* Female subject of child-bearing potential has a negative urine or serum pregnancy test.~* Subject has had or is scheduled to have a chest X-ray within 24 hours prior to the investigational imaging study.~Exclusion Criteria:~* Subject has been administered any other radiopharmaceutical within a timeframe that might cause interference with study imaging.~* Subject is a pregnant or lactating female.~* Subject has received Technegas in the past.~* Subject has received an investigational drug within 30 days prior to dosing.~* Subject is hemodynamically unstable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xe-133 Followed by Technegas (Type: OTHER): Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).